Efficient Wnt mediated intestinal hyperproliferation requires the cyclin D2-CDK4/6 complex

Cell Division

Volumn 6, Issue , 2011, Pages

  Myant, Kevin ^a   Sansom, Owen ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 79251632428     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-6-3     Document Type: Note

References (24)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
2. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28:2925-2939. 10.1038/onc.2009.170, 19561645.
3. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998, 18:753-761. 108786, 9447971.
4. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12:2245-2262. 10.1101/gad.12.15.2245, 9694791.
5. Sherr CJ. Cancer cell cycles. Science 1996, 274:1672-1677. 10.1126/science.274.5293.1672, 8939849.
6. Riabowol K, Draetta G, Brizuela L, Vandre D, Beach D. The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell 1989, 57:393-401. 10.1016/0092-8674(89)90914-8, 2541912.
7. Furuno N, den Elzen N, Pines J. Human cyclin A is required for mitosis until mid prophase. J Cell Biol 1999, 147:295-306. 10.1083/jcb.147.2.295, 2174228, 10525536.
8. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
9. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602:73-87.
10. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009, 220:292-296. 10.1002/jcp.21791, 2874239, 19415697.
11. Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A, Gheber L. Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 2005, 93:338-345. 10.1038/sj.bjc.6602709, 2361572, 16012517.
12. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166. 10.1038/nrc2602, 19238148.
13. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR, Muncan V, Clevers H, Clarke AR, Sicinski P, Sansom OJ. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 70:8149-8158. 10.1158/0008-5472.CAN-10-0315, 20736363.
14. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, Batlle E, Simon-Assmann P, Clevers H, Nathke IS, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004, 18:1385-1390. 10.1101/gad.287404, 423189, 15198980.
15. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679. 10.1038/nature05674, 17377531.
16. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. Embo J 1999, 18:5321-5333. 10.1093/emboj/18.19.5321, 1171602, 10508165.
17. Eilers M. Control of cell proliferation by Myc family genes. Mol Cells 1999, 9:1-6.
18. Athineos D, Sansom OJ. Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine. Oncogene 29:2585-2590. 10.1038/onc.2010.5, 20140021.
19. Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, Clarke AR. Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem 2005, 280:28463-28467. 10.1074/jbc.M500191200, 15946945.
20. Wilding J, Straub J, Bee J, Churchman M, Bodmer W, Dickson C, Tomlinson I, Ilyas M. Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (Min) mice. Cancer Res 2002, 62:4562-4565.
21. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007, 110:2075-2083. 10.1182/blood-2007-02-071266, 17537993.
22. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004, 3:1427-1438.
23. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U, Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 107:1565-1570. 10.1073/pnas.0908682107, 2824379, 20080688.
24. Marsh V, Winton DJ, Williams GT, Dubois N, Trumpp A, Sansom OJ, Clarke AR. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet 2008, 40:1436-1444. 10.1038/ng.256, 19011632.